Navigation Links
1960s-era anti-cancer drug points to treatments for Lou Gehrig's disease
Date:6/13/2012

A long-used anti-cancer drug could be a starting point to develop new treatments for the incurable nerve disease known as Lou Gehrig's disease or amyotrophic lateral sclerosis (ALS), scientists are reporting. Their research showing how the drug prevents clumping of an enzyme linked to ALS appears in the Journal of the American Chemical Society.

Lucia Banci, Ivano Bertini and colleagues explain that ALS causes a progressive loss of muscle control as the nerves that control body movements wither and die. Patients become weak and have difficulty swallowing and breathing, and most die within three to five years of diagnosis. Although some ALS cases are hereditary and run in families, about 90 percent are "sporadic," with the cause unknown. Some research links sporadic ALS to clumping of an antioxidant enzyme called hSOD1. The authors explored whether cisplatin, a chemotherapy drug used since the 1960s that is known to interact with some of the enzyme's amino acids, has any effect on hSOD1 clusters.

The scientists found that in laboratory tests, the anti-cancer drug cisplatin bound readily to the enzyme, preventing hSOD1 from aggregating and dissolving existing bunches. Cisplatin targets sites that can form bonds between hSOD1 after the enzyme loses the atom of copper it normally carries. The scientists note that cisplatin does not prevent the enzyme from performing its normal functions. "From this work it appears that cisplatin is a promising lead compound for the rational design of ALS treatments," the authors say.


'/>"/>

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society
Source:Eurekalert

Page: 1

Related medicine news :

1. Moffitt Cancer Center researchers develop and test new anti-cancer vaccine
2. More Research Points to Long-Term Ills With Bone Drugs
3. Research With Dogs Points to Early Test for Arthritis
4. Study Pinpoints New Abnormality in Athletes Heart
5. Experimental Chemo Combo for Colon Cancer Disappoints
6. Pre-op Treatments Boost Survival for Esophageal Cancer Patients: Study
7. LA BioMeds Dr. Patricia Dickson researching treatments for neurodegenerative disorders
8. Study examines treatments for relieving breathing difficulties among patients with lung effusions
9. Researchers make promising discovery in pursuit of effective lymphoma treatments
10. Research May Point to New Obesity Treatments
11. Feelings of immaturity accompany alcohol misuse into adulthood; discovery could improve treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , ... June 26, 2016 , ... On June 10-11, ... of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, ... the city’s history as home to some of the world’s leading providers of cereal ...
(Date:6/26/2016)... ... ... Kasmer, a legally blind and certified personal trainer is helping to develop a weight loss ... plans to fix the two major problems leading the fitness industry today:, ... , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 26, 2016 One of Australia,s ... the formation of a new biotechnology company, Noxopharm Limited [ABN 50 ... an IPO and to list on the ASX. Noxopharm ... ready to enter a Phase 1 clinical study later this year. ... address one of the biggest problems facing cancer patients - the ...
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
Breaking Medicine Technology: